Silo Pharma Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Public

  • Employees
  • 3

Employees

  • Stock Symbol
  • SILO

Stock Symbol

  • Investments
  • 5

  • Share Price
  • $1.74
  • (As of Friday Closing)

Silo Pharma General Information

Description

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.

Contact Information

Formerly Known As
Gold Swap, Point Capital, Uppercut Brands
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 677 North Washington Boulevard
  • Sarasota, FL 34236
  • United States
+1 (718)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 677 North Washington Boulevard
  • Sarasota, FL 34236
  • United States
+1 (718)

Silo Pharma Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Silo Pharma Stock Performance

As of 20-Nov-2026, Silo Pharma’s stock price is $1.74. Its current market cap is $3.69M with 2.16M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.74 $1.88 $1.10 - $10.42 $3.69M 2.16M 65.8K -$2.29

Silo Pharma Financials Summary

As of 30-Sep-2026, Silo Pharma has a trailing 12-month revenue of $36.1K.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV (2,785) (1,410) (4,024) (4,294)
Revenue 36 72 72 72
EBITDA (3,836) (4,373) (4,715) (4,025)
Net Income (3,720) (4,228) (4,393) (3,701)
Total Assets 8,796 7,605 7,412 7,746
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Silo Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Silo Pharma‘s full profile, request access.

Request a free trial

Silo Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserve
Drug Discovery
Sarasota, FL
3 As of 2025

Radnor, PA
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Silo Pharma Competitors (3)

One of Silo Pharma’s 3 competitors is Marinus Pharmaceuticals, a Private Equity-Backed company based in Radnor, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Marinus Pharmaceuticals Private Equity-Backed Radnor, PA
Ovid Therapeutics Formerly VC-backed New York, NY
Neurona Therapeutics Formerly VC-backed South San Francisco, CA
You’re viewing 3 of 3 competitors. Get the full list »

Silo Pharma Patents

Silo Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026152055-A1 Combination therapy against stress-induced pathophysiology Pending 13-Jan-2025
US-20250288540-A1 Methods and compositions for pain management Pending 13-Mar-2024
US-20240252579-A1 Use of cns-homing targeting peptides for treating neurological disorders Pending 30-Jan-2023
US-20240058469-A1 Use of psilocybin in cancer treatment Pending 13-Dec-2020
WO-2022125949-A1 Use of psilocybin in cancer treatment Inactive 13-Dec-2020 A61P35/00
To view Silo Pharma’s complete patent history, request access »

Silo Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Silo Pharma Investments & Acquisitions (5)

Silo Pharma’s most recent deal was a Merger/Acquisition with Qwikagents for . The deal was made on 15-Apr-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Qwikagents 15-Apr-2026 Merger/Acquisition Application Software
Obesity Treatment Development (Hoth Therapeutics / Silo Pharma) 25-Jun-2025 Joint Venture Drug Discovery
Joint Venture (Silo Pharma / Zylo Therapeutics) 11-Aug-2021 Joint Venture Drug Discovery
Blind Faith Concepts 20-Dec-2018 Merger/Acquisition Footwear
NFID Brands 29-Sep-2018 Merger/Acquisition Clothing
To view Silo Pharma’s complete investments and acquisitions history, request access »

Silo Pharma ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

44.17 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Silo Pharma’s complete esg history, request access »

Silo Pharma Exits (2)

Silo Pharma’s most recent exit was on 20-Dec-2018 from Blind Faith Concepts. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Blind Faith Concepts 20-Dec-2018 Completed
NFID Brands 29-Sep-2018 Merger/Acquisition Completed
To view Silo Pharma’s complete exits history, request access »

Silo Pharma Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Qwikagents

Silo Pharma FAQs

  • When was Silo Pharma founded?

    Silo Pharma was founded in 2010.

  • Where is Silo Pharma headquartered?

    Silo Pharma is headquartered in Sarasota, FL.

  • What is the size of Silo Pharma?

    Silo Pharma has 3 total employees.

  • What industry is Silo Pharma in?

    Silo Pharma’s primary industry is Drug Discovery.

  • Is Silo Pharma a private or public company?

    Silo Pharma is a Public company.

  • What is Silo Pharma’s stock symbol?

    The ticker symbol for Silo Pharma is SILO.

  • What is the current stock price of Silo Pharma?

    As of 20-Nov-2026 the stock price of Silo Pharma is $1.74.

  • What is the current market cap of Silo Pharma?

    The current market capitalization of Silo Pharma is $3.69M.

  • What is Silo Pharma’s current revenue?

    The trailing twelve month revenue for Silo Pharma is $36.1K.

  • Who are Silo Pharma’s competitors?

    Marinus Pharmaceuticals, Ovid Therapeutics, and Neurona Therapeutics are competitors of Silo Pharma.

  • What is Silo Pharma’s annual earnings per share (EPS)?

    Silo Pharma’s EPS for 12 months was -$2.29.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process